What is LKC Technologies?
Established in 1975, LKC Technologies has carved a significant niche in the medical device industry, specializing in visual electrophysiology products. Their flagship RETeval® device, a portable, non-invasive ERG system, has become a cornerstone for diagnosing retina and optic nerve diseases in both clinical and research settings worldwide. With over 40 years of experience, LKC Technologies offers comprehensive visual electrophysiology solutions utilized in over 60 countries for human and veterinary applications. The company's commitment to innovation is underscored by six granted patents and three pending applications, alongside multiple Small Business Innovative Research (SBIR) grants from the National Institutes of Health. LKC Technologies also holds FDA registration and maintains necessary international certifications and device clearances, solidifying its global market presence.
How much funding has LKC Technologies raised?
LKC Technologies has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in LKC Technologies
PPP
Public-Private Partnership
What's next for LKC Technologies?
As LKC Technologies navigates its large-scale late-stage funding phase, the company is strategically positioned to amplify its market leadership. This significant capital injection is anticipated to accelerate research and development, potentially leading to new product innovations and enhancements to their existing portfolio. Furthermore, the funding will likely support expanded global outreach, strengthening distribution networks and increasing market penetration in key international regions. LKC Technologies' established track record, robust patent portfolio, and regulatory compliance provide a strong foundation for leveraging this investment to drive sustained growth and solidify its position as an industry frontrunner in visual electrophysiology.
See full LKC Technologies company page
